BioCentury
ARTICLE | Clinical News

BIT225: Phase II ongoing

March 21, 2011 7:00 AM UTC

Biotron began enrollment of a second set of 12 patients in a double-blind, placebo-controlled, Thai Phase II trial to evaluate 200 or 400 mg BIT225 in combination with Pegasys peginterferon alfa-2a a...